AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05472415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: arch support insoles
Description: The FootDisc insole is designed with curEVA for shock absorption and motion reduction, poron for secondary heel and metatarsal protection, and dynamic arch support for returning energy for propulsion
Study NCT05522972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Game Vision Training
Description: A new approach for improving amblyopic vision using video games
Study NCT05522972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceptual Learning
Description: A new approach for improving amblyopic vision with perceptual learning
Study NCT05522972 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Occlusion Therapy
Description: Conventional treatment for amblyopia
Study NCT05879432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSALT Peptide
Description: LSALT, a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH, binds to dipeptidase-1 (DPEP-1) but does not inhibit its biologic enzymatic activity, potentially minimizing off-target or other adverse effects. LSALT peptide inhibits leukocyte recruitment in multiple experimental disease models through the direct inhibition of leukocyte adhesion to DPEP-1 present in lungs, kidney, and liver.
Study NCT05879432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline solution
Study NCT04768985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Acalabrutinib tablet
Description: Participants will receive fixed single doses of acalabrutinib tablet in 2 treatment periods, under fasted conditions.
Study NCT04768985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Acalabrutinib capsule
Description: Participants will receive fixed single doses of acalabrutinib capsule in 2 treatment periods, under fasted conditions.
Study NCT06562010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCT-SAD-PK
Description: The intervention arm will receive a Pakistani version of Internet-delivered Cognitive Therapy for Social Anxiety Disorder (iCT-SAD), assessing its effectiveness in reducing social anxiety symptoms among Pakistani individuals. This will involve culturally tailored online therapy modules, therapist support, and regular progress assessments.
Study NCT05819684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-4602 for injection
Description: be administered via intravenous (IV) infusion
Study NCT05776797 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrioventricular junction ablation in patients with cardiac resynchronization therapy (CRT)
Description: Ablation of the atrioventricular (AV) node is a procedure used to disrupt or break the electrical connection between the upper heart chambers (the atria) and the lower heart chambers (the ventricles).
Study NCT05776797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medication treatment in patients with cardiac resynchronization therapy (CRT)
Description: Optimal medication therapy according to the prescription of the physician.
Study NCT05683418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOS-358
Description: Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor
Study NCT06553547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Description: Tenapanor 5 mg/mL solution
Study NCT06553547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo solution
Study NCT05635162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib dose is 160 mg twice daily (BD) orally (PO) on days 1-28 of each 28-day cycle.
Study NCT05635162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 intravenous (IV)\* on day 1 (+/-3 days) of each 28-day cycle
Study NCT05501704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Taken orally
Study NCT05804786 — intervention group
Intervention type: DEVICE
Intervention: Guided bronchoscopy
Description: It is performed when a pulmonary lesion with a possibility of malignancy is found on chest CT and histological diagnosis and differentiation are required.
Study NCT04431518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JULUCA 50Mg-25Mg Tablet
Description: One dose of JULUCA will be taken daily for up to 14 days
Study NCT04431518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JULUCA 50Mg-25Mg Tablet
Description: One dose of JULUCA will be taken daily for up to 14 days
Study NCT05809180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375mg/m2 ivgtt d1;
Study NCT05809180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib 150mg per day oral administration till progresses or intolerant toxicity;
Study NCT05809180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide 4mg d1-7 each cycle. After Phase II of treatment, single agent pomalidomide 4 mg d1-d7 in 21-day cycles for 2 years.
Study NCT05809180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pro-miniCHOP-like regimen
Description: rituximab 375mg/m2 ivgtt d1; orelabrutinib 150mg per day oral administration till progresses or intolerant toxicity; pomalidomide 4mg d1-7; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.
Study NCT05809180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-miniCHOP-like regimen
Description: rituximab 375mg/m2 ivgtt d1; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.
Study NCT05621252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLN-74809
Description: 160 mg PLN-74809
Study NCT05621252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT05714293 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT scan with contrast medium
Description: Multi-detector CT scan (if possible with prospective-ECG gated sequential scan) with contrast medium injection of nonionic contrast agent. All CT datasets will be analysed for the qualitative and quantitative assessment of the aortic root. The coronary height will be assessed at baseline in relation to the aortic annulus and in relation to the stent of the bioprostheses after aortic valve replacement.
Study NCT02544815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: Digoxin 0.25 mg pills
Study NCT02544815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills
Study NCT06636487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pulmonary tele-rehabilitation (PTR)
Description: PTR is delivered from promoter hospital to a group of 3 - 5 patients who exercise at home and communicate via tablet-camera. Each session is 60 min; 35 min exercise/ 25 min patient education, two times per week for a duration of 10-weeks.~Specific exercises are evidence-based; been used in several intervention studies on patients with CRD (eg. COPD). Exercises involves larger muscle groups with 50/50 exercises for upper and lower extremities. Volume, intensity and content exercise protocol follow both national and international exercise recommendations. The education sessions consist of dialogue, reflections around empowerment and better living with CRD. Every sixth education session consists of 25 min Mindfulness exercises developed for CRD patients.~After 10-weeks of PTR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period
Study NCT06636487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation (HPR)
Description: HPR is an individual self-initiated home-based PR aiming to achieve 20 min of self-initiated muscle endurance based exercise; 3-days/weekly for 10-weeks. Exercises are evidence based; used in several intervention studies on patients with CRD (eg. COPD) and involves larger muscle groups with 50/50 exercises for upper/lower extremities.~First session is a home visit by a respiratory physiotherapist. During the visit the physiotherapist and patient establish exercise goals, exercise prescription and provision of access to mindfulness exercises and an educationbook. The home visit is followed by one weekly session for 10-weeks. A menu of topics relevant to CRD and self-management is discussed. A session is delivered from promoter hospital via tablet-camera or telephone call (patients preference).~After 10-weeks of HPR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period
Study NCT06636487 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Receive usual care; medication, scheduled follow up visit and possible phone contact with GP and the outpatient respiratory department. Except for assessment visits 10-, 35-, and 75-weeks from baseline no intervention is offered. If a patient changes their decision and wishes to participate in a conventional hospital- or community-based PR program, it will be granted as this is a highly recommended treatment (e.g. rehabilitation after hospital admitted exacerbation).
Study NCT06631339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light Intervention
Description: LEDs mimicking the spectrum of sunlight (4000K) administered daily for 1 academic year, every school day, for the entire school day. The light levels generated by these LEDs will fluctuate throughout the day but will remain under 1000 lux.
Study NCT06631339 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Intervention
Description: Smart-phone application (LightUP) will be synced daily to a child-worn light and activity sensor and will allow parents to track their children's outdoor time and exposure to brighter light levels across the day. The application will also nudge parents to increase their child's exposure to light (e.g., increase time outdoors, or sitting next to a window indoors) after school hours for better myopia prevention and control. i-LightUP aims to gradually assist parents in helping their children reach the ultimate goal of spending at least 2 hours per day in brighter light conditions (e.g., above 1000 lux).
Study NCT06631339 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Standard Classroom Lighting + Sham LightUP phone application
Study NCT05726630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divozilimab
Description: anti CD20 monoclonal antibody
Study NCT05726630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06258304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIGA-564
Description: Administered by intravenous infusion
Study NCT05568095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Intravenous (IV) Aqueous Solution
Study NCT05568095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: IV Aqueous Solution
Study NCT05568095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral Tablets
Study NCT05568095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Oral Tablets
Study NCT05568095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: IV Aqueous Solution
Study NCT05568095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: IV Aqueous Solution
Study NCT05568095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: IV Aqueous Solution
Study NCT05568095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: IV Aqueous Solution
Study NCT05568095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV Aqueous Solution
Study NCT05568095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: IV Aqueous Solution
Study NCT05501704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Taken orally
Study NCT05568095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: IV Aqueous Solution
Study NCT04920292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxfendazole
Description: Oxfendazole is a benzimidazole anthelminthic drug.
Study NCT04920292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo tablet is made using the same non-active ingredients and matches the investigational tablet.
Study NCT04869917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid intervention
Description: * Displays information about the benefits and risks of ILI and metformin~* Asks open-ended questions: What am I willing to do to prevent T2D? and What do I need to prevent T2D?~* Prompts patients to commit to immediate next steps~* Health educator schedules interested patients for first ILI session or sends message to provider about patients' interest in starting metformin, if chosen
Study NCT05501704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Subcutaneous (under the skin) injection
Study NCT04778358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin Delta, Recombinant
Description: 15 µg of follitropin delta will be administered subcutaneously daily
Study NCT05501704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Taken orally
Study NCT05038332 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultra-hypofractionated radiation therapy
Description: 34 Gy in 5 fractions to prostate bed, every other day, M-F, \~2 weeks (25 Gy in 5 fractions to pelvic lymph nodes if included)
Study NCT05038332 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Moderately Hypo-fractionated Radiation Therapy
Description: 55 Gy in 20 fractions to prostate bed, daily, M-F, 4 weeks (42 Gy in 20 fractions to pelvic lymph nodes if included)
Study NCT05299606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transbronchial Microwave Ablation
Description: Transbronchial microwave ablation will be performed using the NEUWAVE FLEX Microwave Ablation System and Accessories on oligometastatic tumors in the peripheral lung, guided by the Auris MONARCH Platform for visualization and access while using cone beam CT (computed tomography) to confirm probe tip placement and final ablation zone.
Study NCT05615558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Controlled dietary intervention; all food is provided to participants after being allocated to animal or non-animal dietary protein, for a duration of 5 weeks.
Study NCT05590312 — intervention group
Intervention type: OTHER
Intervention: general anesthesia
Description: All patients will undergo general anesthesia. Group D will receive fresh gas flow of 1 l/min and Group Y will receive fresh gas flow of 4 l/min.
Study NCT06642428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy + vitamin D2
Description: Before the start of treatment and every 3 weeks thereafter, participants will receive injections of vitamin D2 at a dosage of 10 mg until the completion of neoadjuvant therapy. They will undergo the standard neoadjuvant regimen, which includes the 10 mg injection of vitamin D2 per cycle during the therapy. The dosage of neoadjuvant drugs may be tailored based on the physician's clinical judgment.
Study NCT06642428 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Neoadjuvant therapy
Description: Participants will receive the standard neoadjuvant regimen during each cycle of neoadjuvant therapy. The dosage of the neoadjuvant drugs may be tailored based on the physician's clinical judgment.
Study NCT06082739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Stretching exercises with and without a bolster, ball, or foam roller.
Study NCT06249984 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05174806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Pravibismane
Description: Topical Pravibismane
Study NCT05174806 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of care treatment without investigational topical pravibismane (MBN-101) or other topical antibiotics.
Study NCT06095284 — intervention group
Intervention type: OTHER
Intervention: Pre-Extraction Phase
Description: This intervention requires the following procedures: Submitting data use agreement, MDS request defined and developed, Part D request, CMS public use file request defines and develop questionnaire
Study NCT04869917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging intervention
Description: * Defines prediabetes and includes individualized A1c values~* Present benefits and risks of intensive lifestyle intervention and metformin~* States that other prediabetic Erie patients are adopting intensive lifestyle intervention and metformin~* Encourages initiating intensive lifestyle intervention or discussing metformin with provider~* Include selected behavioral content from diabetes prevention program~* Initial message with automatic opt-in, allows opt-out for messages~* Subsequent messages include: information about T2D risk and treatments; prompts to directly schedule intensive lifestyle intervention or office visit to discuss metformin; selected behavioral content from diabetes prevention programming
Study NCT04869917 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Patients receiving care at non-intervention clinic sites will not be exposed to treatment intervention.
Study NCT05964868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: Patients will receive post-operative liposomal bupivacaine (EXPAREL®) at the surgical site at the completion of their septorhinoplasty.
Study NCT05964868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% bupivacaine with 1:200,000 epinephrine
Description: Non-liposomal encapsulated bupivacaine at the surgical site at the completion of septorhinoplasty.
Study NCT05964868 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Saline solution
Description: This group will receive a one-time 5 mL injection of saline post-operatively at the surgical site.
Study NCT04122690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PDAE
Description: Participants with PD will dance the follower role only and will dance with new partners (individuals without PD) every 15-20 minutes, a widely practiced method considered by the dance teaching community to enhance learning. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Frequent repetition and musical stereotypes may foster implicit learning or muscle memory (i.e., motor learning, or procedural memory that involves consolidating a specific motor task into memory through repetition). Participants will not be required to memorize specific step patterns but will learn new steps in each class
Study NCT04122690 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WAE
Description: The participants will receive equal contact and monitoring from study staff. WAE participants will report to the same facility and interact with the same interventionist and assistants. The participants will participate in sessions focused on at least 60 minutes of walking with breaks ad libitum, and 1/2 hour balance and stretching. The investigators have a designated, safe and non-cluttered area for walking. WAE will also take place in groups, with research volunteers and assistants to ensure that PDAE and WAE participants both receive a socially engaging intervention
Study NCT06018116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg
Description: nonsteroidal antiandrogen
Study NCT06095284 — intervention group
Intervention type: OTHER
Intervention: Extraction Phase
Description: Procedures include: Access VRDC for 2 years, Crosswalk CMS files and MDS using ID's, Preliminary analysis for validity/accuracy, Request revision/resubmission, Linked dataset created in VRDC and Distribute Questionnaire
Study NCT06095284 — intervention group
Intervention type: OTHER
Intervention: Post-Extraction Phase
Description: Procedures include: De-identified data securely stored, analysis, dissemination and knowledge translation
Study NCT05683275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IASTM
Description: IASTM will be applied to the affected extremity twice a week for 4 weeks, in total 8 sessions. Participants will be asked to sit comfortably in a chair with back support. IASTM will be applied to the wrist extensor muscles of the participants for 90 seconds in the position where the muscle is tense, with a frequency of 60 beats per minute.
Study NCT05683275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESWT
Description: ESWT will be applied to the affected elbow two days a week for 4 weeks, a total of 8 sessions, each session 2000 shock 10 Hz frequency, 2.5 bar intensity point and circumferential application.